Aspira Women’s Health Kicks Off Ovarian Cancer Awareness Month by Further Establishing Itself as a Thought Leader in Ovarian Cancer

2021-09-09

AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heralding the beginning of Ovarian Cancer Awareness Month, Aspira Women’s Health, Inc (“Aspira”) (Nasdaq: AWH) will ring the closing bell at NASDAQ on Thursday, September 9, 2021 to signal a call to action for progress in ovarian cancer awareness, access to important risk assessment technology, and research. The closing bell ceremony will begin at approximately 3:45pm EDT. A livestream of the Nasdaq Closing Bell will be available at Despite decades of research, ovarian cancer remains one of the most lethal of gynecological cancers. In the United States, it ranks as the fifth highest cause of cancer death in women, even though its incidence---1.3% of all new annual cancer cases—is relatively low. Unfortunately, the onset of ovarian cancer is usually quite insidious, with symptoms that mimic much less serious conditions, thereby earning it the unsettling nickname of “the cancer that whispers.” It actually does NOT whisper as women often ignore or dismiss the bloating, back pain, appetite loss, vaginal bleeding, or urinary disturbances that can be the “alarm bell” that malignancy is present. In fact, many health care professionals exhibit the same response when alerted to these symptoms by women because they are so generic. The end result is that when ovarian cancer is finally detected in the majority of women, it has progressed to stage III or IV disease, when five-year survival rates can be as low as 27%. Aspira Women’s Health Inc. has been increasing access for women to important risk assessment tools and building awareness of our company’s solutions and its brand thru new guidelines, direct to provider education at the local, regional and national level including participating in a congressional briefing in March 2021 regarding the need to fund diversity trials and support MCIT breakthrough technology at the FDA as well as a presentation given by Kaile Zagger, our Chief Operating Officer, at a FemTech Industry Landscape in July 2021 titled “Changing the story through transformation, A New Paradigm in Early Detection of Ovarian Cancer.” During the month of September---Ovarian Cancer Awareness Month—we are bringing awareness to our solutions and our mission to transform women’s health by participating in and sponsoring several events. September 14-15 - Women’s Health Innovation Summit, Boston, MA, September 27- Ovarian Cancer Awareness Month Congressional Briefing “Aspira continues to make great strides towards goal of developing innovative testing options and bioanalytical solutions to significantly improve women’s healthcare, starting with ovarian cancer,” emphasizes Valerie Palmieri. “Participating in these events during Ovarian Cancer Month, coupled with the tools we are able to provide clinicians, will increase not only women’s overall awareness but health care providers’ awareness of this disease and the new opportunities for early detection.” About ASPIRA Women’s Health Inc.Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus combines our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans. The next generation of products in development are OVAWatchTM and EndoCheckTM. Visit our website for more information at . Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLCTel 617-430-7577Arr@lifesciadvisors.com

机构